发布于: 修改于:Android转发:1回复:1喜欢:0
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
$阿里拉姆制药(ALNY)$ $罗氏控股(RHHBY)$
找个大厂风险共担挺好的,不过,罗氏心血管不是优势TA,也没什么产品

全部讨论

2023-07-24 13:20

– Alnylam will Receive an Upfront Cash Payment of $310 Million and is Eligible to Receive Development, Regulatory, and Sales Milestones, Including Substantial Near-Term Milestones, for a Potential Deal Value of up to $2.8 Billion, as well as an Equal Share of Profits and Losses in the United States and Royalties on Net Sales Outside the U.S. –